micro-community-banner
 
  • Saved

2yr
Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma - PubMed

Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37229538/

Brexucabtagene autoleucel is a chimeric anti CD19 antigen receptor T-cell therapy that allows durable responses in relapsed/refractory (R/R) mantle cell lymphoma (MCL). The present study compared the clinical and economic...

Conclusions/Relevance: The model compared brexucabtagene autoleucel strategy to R-BAC and was based on the assumption that progression-free patients after 5 years do not incur any relapse, namely are assumed functionally cured. In the lifetime horizon, the model estimated that brexucabtagene autoleucel delivered 5.2 discounted QALYs over...

  • Saved

2yr
2023 American Society of Clinical Oncology Annual Meeting

The American Society of Clinical Oncology (ASCO) will host its annual meeting at McCormick Place in Chicago from June 2 to 6, 2023. The theme of this year’s conference is Partnering With Patients: The Cornerstone of Cancer Care and Research. Click to access a preview into the conference topics.

  • Saved

2yr
Amino-Pyrazoles in Medicinal Chemistry: A Review - PubMed

Amino-Pyrazoles in Medicinal Chemistry: A Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37175540/

A pyrazole nucleus is an easy-to-prepare scaffold with large therapeutic potential. Consequently, the search for new pyrazole-based compounds is of great interest to the academic community as well as industry....

Conclusions/Relevance: With the aim to fill this gap, the present review article focuses on aminopyrazole-based compounds in different therapeutic fields, with particular attention to the design and structure-activity relationship (SAR) aspects of each class of compounds, to provide better correlation among different currently ongoing...

  • Saved

2yr
Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax - PubMed

Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37206291/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....

Conclusion: Splenectomy plus polatuzumab-based regimen was an effective bridging to CAR T cells therapy in our patient with high tumour burden R/R cMCL. This approach is worth to be explored in patients presenting with the same characteristics.

  • Saved

2yr
Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure-activity relationship

Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure-activity relationship

Source : https://www.sciencedirect.com/science/article/abs/pii/S0045206823002389?via=ihub

Protein kinases constitute the largest group within the kinase family, and mutations and translocations of protein kinases due to genetic alterations ...

Conclusions/Relevance: This article systematically summarizes recently discovered covalent and non-covalent BTK inhibitors and classifies them according to their structures. This article also provides a detailed discussion of binding modes, structural features, pharmacological activities, advantages and limitations of typical compounds within...